CD34 and autosomal dominant cerebellar ataxia: The successful introduction of a SB therapeutic transgene into CD34+ cells from an SCA patient and in vitro evidence of its ability to improve the sickling characteristics of these cells are important milestones in developing this non-viral gene therapy system.